United States & Kenvue

United States: Jurisdiction; political involvement via Trump administration; FDA and CDC mentioned.

Kenvue: Primary defendant; faces revived lawsuits alleging failure to warn about autism/ADHD risk. Stock fell 1% on ruling.

United States: US state EPR laws create a favorable regulatory environment for Greyparrot's expansion.

Kenvue: Kenvue partnered with Greyparrot to improve recycling for its packaging, using Deepnest to validate performance.

United States: The United States is a major market where Kimberly-Clark saw a slight volume decline due to inflation and consumer spending cuts. This adds to the company's challenges.

Kenvue: Kenvue is the target of Kimberly-Clark's roughly $40 billion acquisition, expected to close by year-end. The acquisition is part of Kimberly-Clark's strategy, though the China disruption may affect the deal's timing or financing.

United States: The settlement resolves claims in U.S. federal and state courts, covering nearly all remaining talc lawsuits in the country.

Kenvue: Kenvue, J&J's former consumer health business, holds liability for Johnson's baby powder outside North America but is not directly involved in the U.S. settlement.

Kenvue: Kenvue, the manufacturer of Tylenol, strongly disagreed with the suggestion that acetaminophen causes autism, defending the drug's safety and warning of risks from untreated fever or pain.

Kenvue: Kenvue, formerly Johnson & Johnson's consumer health unit, retained responsibility for talc-related litigation outside the United States and Canada after its spin-off in 2023. It is named as a defendant in the UK lawsuit and maintains that its talc products are safe and asbestos-free.

Kenvue: Kenvue is being acquired by Kimberly-Clark for $48.7 billion, providing a significant premium to its shareholders. Kenvue's stock surged after the announcement, despite facing scrutiny over Tylenol and activist investor pressure.

Kenvue: Kenvue, the manufacturer of Tylenol (paracetamol), faced a lawsuit regarding alleged links between its product and autism, which was dismissed. The new study supports the safety of its product.